Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

Fremont, California, October 9, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. Gavin Samuels, M.D., Senior Vice President of Business Development will be presenting.

Event: CIBC World Markets 18th Annual Healthcare Conference
Date: Tuesday, November 6, 2007
Time: 8:30 a.m. ET
Place: The Waldorf-Astoria Hotel, New York

Event: Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date: Tuesday, November 6, 2007
Time: 11:40 a.m. ET
Place: New York Palace Hotel, New York

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development and includes:

• A proprietary gene discovery platform (BiFAR™) and algorithm for optimizing siRNA sequencing
• Novel siRNA structures that the Company believes provide Quark with freedom to operate in the crowded siRNA intellectual property arena for its future product pipeline
• The ability to deliver siRNA locally and systemically to organs including eye, ear, kidney, lung, spinal cord and bone marrow

Quark has a robust product portfolio including two clinical, one pre-IND and six preclinical candidates in development. Its lead product candidates are RTP801i-14, an siRNA molecule in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration that is licensed to Pfizer on an exclusive worldwide basis, AKIi-5, an siRNA molecule for the prevention of acute kidney injury / acute renal failure, and AHLi-11, an siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss.
Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com